- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04742725
A Study to Evaluate the Efficacy and Safety of Prothione™ Capsules for Mild to Moderate Coronavirus Disease 2019 (COVID-19)
A Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Prothione™ Capsules for Mild to Moderate Coronavirus Disease 2019 (COVID-19)
The study is a phase 2 proof of concept study. The purpose of this study is to assess the efficacy and safety of Prothione™ capsules administered orally twice a day for 30 days in subjects with mild to moderate COVID-19. The study will have three phases: Screening Period, Treatment Period, and Follow-Up Period.
The issued patents relevant to Prothione™ capsules and the treatment of viral disease include: • Nutritional or Therapeutic Compositions and Methods to Increase Bodily
Glutathione Levels:
- US Patent No. RE 42,645
- Japanese Patent No. 5601745
- European Patent No. 1556023
- Canadian Patent No. 2539567
Australian Patent No. 2010201136
• Protective Metallothionein Analog Compounds, Their Compositions and Use
Thereof in the Treatment of Pathogenic Disease:
- Canadian Patent No. 2963131
- Australian Patent No. 2018279015
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Phase 2, proof of concept, two-arm, randomized, double blind, placebo-controlled study to evaluate the safety and efficacy of Prothione™ capsules in subjects with mild-to-moderate symptoms caused by coronavirus 2019 (COVID-19) infection. Subjects will be randomized to receive three Prothione™ capsules, or placebo orally administered twice daily (BID).
The study will have three phases: screening period, treatment period, and follow-up period. Screening period is up to 3 days , the treatment period is 30 days and the follow-up period is 7 days after the last dose.Total study duration is up to 40 days.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Kigali, Rwanda
- Rinda Ubuzima
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Potential subjects are required to meet all of the following criteria for enrollment into the study:
Male or female adult ≥ 18 years of age at time of enrollment with mild to moderate symptoms caused by coronavirus 2019 confirmed infection with COVID-19 by PCR and one or more of the following:
Mild (uncomplicated) Illness:
- Diagnosed with COVID-19 by a standardized RT-PCR assay AND
- Mild symptoms, such as fever, rhinorrhea, mild cough, sore throat, malaise, headache, muscle pain, or malaise, but with no shortness of breath AND
- No signs of a more serious lower airway disease AND RR<20, HR <90, oxygen saturation (pulse oximetry) > 93% on room air
Moderate Illness:
- Diagnosed with COVID-19 by a standardized RT-PCR assay AND
- In addition to symptoms above, more significant lower respiratory symptoms, including shortness of breath (at rest or with exertion) OR
- Signs of moderate pneumonia, including RR ≥ 20 but <30, HR ≥ 90 but less than 125, oxygen saturation (pulse oximetry) > 93% on room air AND
- If available, lung infiltrates based on X-ray or CT scan < 50% present
- Subjects with normal level of Vitamin B2; Note: If the result was below the normal range, based on clinical judgment by physician, appropriate treatment to be added to the subject treatment regimen as per standard of care. A B complex daily supplement will be supplied, if needed.
- Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures;
- Understands and agrees to comply with planned study procedures; and
- Negative pregnancy test for female subjects. Women of child-bearing potential (WOCBP) and Women not of child-bearing potential are eligible to participate. Both women of child-bearing potential and women of no child-bearing potential should use an approved method of birth control and agrees to continue to use this method for the duration of the study (and for 30 days after taking the last dose of Prothione™ ).
Acceptable methods of contraception include abstinence, female subject/partner's use of hormonal contraceptive (oral, implanted, or injected) in conjunction with a barrier method (WOCBP only), female subject/partner's use of an intrauterine device (IUD), or if the female subject/partner is surgically sterile or 2 years post-menopausal. All male subjects/partners must agree to consistently and correctly use a condom for the duration of the study. In addition, subjects may not donate sperm for the duration of the study and for 30 days after taking study drug.
Exclusion Criteria:
Potential subjects meeting any of the following criteria will be excluded from enrollment:
- Subjects showing signs of acute respiratory distress syndrome (ARDS) or respiratory failure necessitating mechanical ventilation at the time of screening;
- Subjects who have history of receiving NAC, Prothione™ Capsules or GSH supplements in the past 30 days before the screening visit;
- Subjects who have history of receiving corticosteroids (topical corticosteroid is excluded) in the past 30 days;
- Subjects who are currently receiving Chemotherapy or Immunotherapy for the treatment of cancer;
- Any uncontrolled active systemic infection requiring admission to an intensive care unit (ICU);
- Subject with active Hepatitis B and Hepatitis C;
- Subjects who are participating in other clinical trials;
- Subjects that have had any Covid19 Vaccination;
- Subjects who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to Prothione™ are not eligible;
- Inability to provide informed consent or to comply with study requirements; and
- Subjects who are pregnant or breast-feeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo
|
Experimental: Prothione ™
|
Prothione is a pro-Glutathione compound includes free-form amino acids
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time (days) to successful clinical recovery from positive RT-PCR for SARS-COV2 as indicated by two consecutive negative RT-PCR tests measured with three different measurements within a 24-36 hour period.
Time Frame: 24-36 hour period
|
24-36 hour period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline to Day 29 in Serum 8-OHdG levels
Time Frame: Baseline to day 29
|
Baseline to day 29
|
|
Change in RBC intracellular Glutathione levels to Day 29
Time Frame: Baseline to day 29
|
Baseline to day 29
|
|
Quantitative change from Baseline (Screening Visit) to Day 29 oropharyngeal cell intracellular GSH levels
Time Frame: Baseline to day 29
|
Baseline to day 29
|
|
Time to clinical resolution (TTCR) defined as the time (days) from initiation of study treatment until reach a score of 0 at least in three of the following: o Fever o Myalgia o Dyspnea o Cough
Time Frame: Baseline to day 29
|
( Each symptom is graded from 0 to 3. [0=none 1=mild 2=moderate and 3=severe]
|
Baseline to day 29
|
Evaluate Cycle Threshold (Ct) numbers used in qualitative and quantitative RT-PCR for SARS-COV2 tests.
Time Frame: Baseline to day 29
|
Baseline to day 29
|
|
Clinical Improvement as assessed by change in symptom score from baseline (for fever, myalgia, dyspnea and cough).
Time Frame: Baseline to day 29
|
Note: The score per patient ranges from 0 to 3 points.
Each symptom is graded from 0 to 3. [0=none, 1=mild, 2=moderate, and 3=severe]
|
Baseline to day 29
|
Mortality at Day 29
Time Frame: Day 29
|
Day 29
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quantitative changes in viral load from baseline (Screening Visit) to Day 29.
Time Frame: Baseline to day 29
|
Exploratory Outcome
|
Baseline to day 29
|
Change from baseline to Day 29 in pulse oxygen saturation (SpO2)
Time Frame: Baseline to day 29
|
Exploratory Outcome
|
Baseline to day 29
|
Change from baseline to Day 29 in Quantitative C-Reactive Protein level
Time Frame: Baseline to Day 29
|
Exploratory Outcome
|
Baseline to Day 29
|
Change from baseline to Day 29 in Lymphocyte Count
Time Frame: Baseline to Day 29
|
Exploratory Outcome
|
Baseline to Day 29
|
Changes in HIV viral load from baseline to Day 29 in HIV positive subjects
Time Frame: Baseline to Day 29
|
Exploratory Outcome
|
Baseline to Day 29
|
Duration (days) of hospitalization
Time Frame: Baseline to Day 29
|
Exploratory Outcome
|
Baseline to Day 29
|
Time(days) to clinical resolution (TTCR) before Day 14
Time Frame: Before Day 14
|
Exploratory Outcome
|
Before Day 14
|
Time (days) to successful clinical recovery from positive RT-PCR for SARS-COV2 as indicated by three consecutive negative RT-PCR tests measured with two different measurements within a 24-36 hour period before Day 14.
Time Frame: within a 24-36 hour period before Day 14
|
Exploratory Outcome
|
within a 24-36 hour period before Day 14
|
Quantitative changes in viral load from baseline (Screening Visit) to Day 14
Time Frame: Baseline to Day 14
|
Exploratory Outcome
|
Baseline to Day 14
|
Change from baseline to Day 14 in Quantitative C-Reactive Protein level
Time Frame: Baseline to Day 14
|
Exploratory Outcome
|
Baseline to Day 14
|
Incidence of treatment-related adverse events (TEAEs)
Time Frame: until day 40
|
Safety Outcome
|
until day 40
|
Incidence and severity of treatment-emergent adverse events (TEAEs)
Time Frame: until day 40
|
Safety Outcome
|
until day 40
|
Incidence of serious adverse events (SAEs)
Time Frame: until day 40
|
Safety Outcome
|
until day 40
|
Incidence of TEAEs and SAEs leading to discontinuation of study medication.
Time Frame: until day 40
|
Safety Outcome
|
until day 40
|
Incidence of abnormal laboratory test results
Time Frame: until day 40
|
Safety Outcome
|
until day 40
|
Changes in body temperature
Time Frame: until day 40
|
Safety Outcome
|
until day 40
|
Changes in pulse rate
Time Frame: until day 40
|
Safety Outcome
|
until day 40
|
Changes in respiratory rate
Time Frame: until day 40
|
Safety Outcome
|
until day 40
|
Changes in systolic and diastolic blood pressure
Time Frame: until day 40
|
Safety Outcome
|
until day 40
|
Incidence of abnormal physical examination findings
Time Frame: until day 40
|
Safety Outcome
|
until day 40
|
Incidence of abnormal electrocardiogram (ECG) results
Time Frame: until day 40
|
Safety Outcome
|
until day 40
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Laura Lile, MD,RPh, Innate FFAAP Medicines, L.L.C.
- Principal Investigator: Vincent Mutabazi, MD, Research, Epidemiology and Training Programs: RASD Rwanda
- Study Chair: Albert Crum, MD, Innate FFAAP Medicines, L.L.C.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TAL-PRO-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronavirus Disease 2019 (COVID-19)
-
AudibleHealth AI, Inc.Sunrise Research Institute; Analytical Solutions Group, Inc.; Kelley Medical... and other collaboratorsCompletedCoronavirus Disease 2019 | SARS-CoV-2 Infection | COVID-19 Pandemic | COVID-19 Virus Infection | Coronavirus Disease-19 | COVID-19 Virus Disease | 2019 Novel Coronavirus Disease | 2019 Novel Coronavirus Infection | 2019-nCoV DiseaseUnited States
-
Leidos Life SciencesUnited States Department of DefenseActive, not recruitingCOVID-19 | Covid19 | Coronavirus Disease 2019 | SARS-CoV-2 Infection | SARS-CoV-2 Acute Respiratory Disease | COVID-19 Pandemic | COVID-19 Virus Infection | COVID-19 Virus Disease | 2019 Novel Coronavirus Disease | 2019 Novel Coronavirus Infection | 2019-nCoV Disease | 2019-nCoV InfectionUnited States
-
Leidos Life SciencesUnited States Department of DefenseWithdrawnCOVID-19 | Covid19 | Coronavirus Disease 2019 | SARS-CoV-2 Infection | SARS-CoV-2 Acute Respiratory Disease | COVID-19 Pandemic | COVID-19 Virus Infection | COVID-19 Virus Disease | 2019 Novel Coronavirus Disease | 2019 Novel Coronavirus Infection | 2019-nCoV Disease | 2019-nCoV Infection
-
Leidos Life SciencesUnited States Department of DefenseTerminatedCOVID-19 | Covid19 | Coronavirus Disease 2019 | SARS-CoV2 Infection | SARS-CoV-2 Acute Respiratory Disease | COVID-19 Pandemic | COVID-19 Virus Infection | COVID-19 Virus Disease | 2019 Novel Coronavirus Disease | 2019 Novel Coronavirus Infection | 2019-nCoV Disease | 2019-nCoV InfectionUnited States
-
CSL BehringCompletedCoronavirus Disease 2019 (COVID-19)United States
-
Guangzhou Institute of Respiratory DiseaseTongji Hospital; Guangzhou Eighth People's Hospital; Guangzhou Cellgenes Biotechnology...UnknownCoronavirus Disease 2019 (COVID-19)China
-
Akesobio Australia Pty LtdCompletedCoronavirus Disease 2019 (COVID-19)New Zealand
-
Materia Medica HoldingActive, not recruitingCoronavirus Disease 2019 (COVID-19)Russian Federation
-
AstraZenecaCompletedCoronavirus Disease 2019 (COVID-19)China
-
Tychan Pte Ltd.Completed
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States